Phase II Pilot Trial of an Indoleamine 2, 3,diosygenase -1 (IDO1) Inhibitor (INCBO24360) Plus a Multipeptide Melanoma Vaccine (MELTAC 12.1) in Patients with Advanced Melanoma (CITN-04)
Clinical Trial Grant
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 21, 2017
End Date
August 31, 2018
Administered By
Medicine, Medical Oncology
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 21, 2017
End Date
August 31, 2018